Document:

EX. 10.56 Illumina Amendment

Exhibit 10.56
***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under 
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

Third Amendment to Sale and Supply Agreement
Sequenom, Inc. (“SQNM”) and Illumina, Inc. (“Illumina”) entered into that certain Sale and Supply Agreement with an effective date of July 8, 2011 as amended by that certain First Amendment to Sale and Supply Agreement, and by that certain Second Amendment to Sale and Supply Agreement (the “Agreement”). SQNM and Illumina desire to amend certain terms of the Agreement pursuant to the terms of this Third Amendment to Sale and Supply Agreement (the “Amendment”).  
By signing where indicated below, SQNM and Illumina hereby agree to amend the terms of the Agreement as follows:
		
	1.
	Page A-1 of Exhibit A of the Agreement (as previously amended by the Second Amendment) is deleted in its entirety and replaced with Attachment 1 to this Amendment.

		
	2.
	SQNM agrees that Illumina invoice numbers 379077, 402150, 404101, 400654, 401098, 402157, 404332, 400656, 401106, which total [...***...], are accurate and reflect amounts owed by SQNM to Illumina.

		
	3.
	This Amendment shall be prospectively effective as of October 1, 2012.  For clarity the terms and conditions of the Agreement as amended by this Amendment shall apply to Consumables shipped beginning October 1, 2012.

		
	4.
	Except as expressly modified herein, the Agreement shall remain in full force and effect in accordance with its terms.  

IN WITNESS WHEREOF, the parties have signed this Amendment as of the dates indicated below.
    
	
					
	ILLUMINA
	 
	SEQUENOM

	

By:
	

/s/ Matt Posard
	 
	By:
	

/s/ Harry Hixson Jr.

	Name:
	Matt Posard
	 
	Name:
	Harry Hixson Jr.

	Title:
	General Manager, Translational & Consumer Genomics
	 
	Title:
	CEO

	Date:
	11/30/12
	 
	Date:
	11/28/12

    

CONFIDENTIAL
1
 
 
807749 v3/SD 

Attachment 1

Consumables

V3 Reagents
	
					
	[...***...] Part Number
	Description
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

[...***...]

[...***...]

[...***...]
	
		
	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

Consumables Purchase Price

The purchase price for all Consumables ordered for shipment in the calendar quarter immediately following the calendar quarter of each Forecast Due Date* (this immediately following calendar quarter being referred to as “Q+1”) is determined by [...***...].

CONFIDENTIAL
3
 
 
807749 v3/SD 

Consumable Spend Calculation 

Consumable Spend for purposes of determining [...***...] as follows:  
		
	1)
	[...***...]

		
	2)
	[...***...]

		
	3)
	[...***...]

		
	4)
	[...***...]

*The Forecast Due Date [...***...].
**Dollar amount [...***...].
***Dollar amount [...***...].  
****Solely for purposes of determining [...***...], the discount rate applicable [...***...].

Formula
[...***...]

CONFIDENTIAL
3
 
 
807749 v3/SDEX. 10.57 Isis Amendment

***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under 
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
  
  
  

DATED 29 November 2012 

ISIS INNOVATION LIMITED AND
SEQUENOM, INC.

FOURTH AMENDMENT 
AGREEMENT

    *** Confidential Treatment Requested
802573 v3/SD 

THIS FOURTH AMENDMENT AGREEMENT is made on 29 November, 2012 (The "Fourth Amendment Agreement Effective Date").

BETWEEN:

(I) ISIS INNOVATION LIMITED (company number 2199542) whose registered office is at University Offices, Wellington Square, Oxford OX1 2JD, England (the "Licensor"); and

(2) SEQUENOM, INC., a Delaware Corporation, whose principal place of business is at 3595
John Hopkins Court, San Diego, CA 92121-1331 USA (the "Licensee").
BACKGROUND:
a) The Licensor granted a license of certain patents, patent applications and associated know-how relating to non-invasive pre-natal diagnosis to the Licensee on 14 October 2005 accompanied by a Development Plan Agreement made on the same date and this license was amended by three subsequent amendment agreements entered into respectively on 19 October 2006, 5 November 2007 and 3 November 2009 (together the "Licence'').

b) The Parties wish to further amend the Licence in accordance with the provisions set out below.

AGREEMENT:

1.  Interpretation

Except as otherwise provided in this Fourth Amendment Agreement, words and expressions used in this Agreement have the same meaning as in the Licence.

2.  Payment

In consideration of the agreement given by the Licensor in clause 3below, the Licensee enters into the covenants in this Fourth Amendment Agreement and the Licensee shall pay to the Licensor (a) the sum of [...***...] US dollars (USD [...***...]) by wire transfer within fifteen (15) business days of the Fourth Amendment Agreement Effective Date and (b) the further sum of [...***...] US dollars (USD [...***...]) to be paid by wire transfer in two equal installments of [...***...] US dollars (USD [...***...]), the first no later than 31 January 2014 and the second no later than 31 January 2015. The sums referred to in this clause 2 are expressed as being exclusive of VAT.  The sums referred to in this clause 2 shall not be creditable in favor of Licensee with respect to any other financial obligation of Licensee under the Licence.

3.  Amendment of -the Licence

With effect on and from the Fourth Amendment Agreement Effective Date the Parties agree as follows:

(a) Clause 11.4.1 shall be amended to read in its entirety as follows

"In the event that Licensee is in the future [...***...], as the result [...***...], then Licensee shall use all reasonable endeavors to [...***...].”

               (b) Clause 11.4.3 shall be deleted in its entirety, 

               (c) a new Clause 10.1.7 shall be added to the Licence as follows: 

“(i) report on any changes by the regulatory authorities (including but not limited to the U.S. FDA) that may impact on the Licensee's ability to lawfully Market Licensed Product for the aneuploidy indication; and 
(ii) in the event there is a requirement to obtain regulatory approval to be able to lawfully Market Licensed Product for the aneuploidy indication in the U.S. (other than the requirements for Laboratory Developed Tests under the U.S. Clinical Laboratory Improvement Amendment of 1988 (“CLIA”), now applicable to the testing service currently offered by Licensee), then set out the activities and timelines that Licensee will undertake to complete clinical development and submit for such regulatory approval.”

    *** Confidential Treatment Requested
802573 v3/SD 

4.  Waiver

The Licensor hereby irrevocably waives, releases and discharges the Licensee from and against any and all claims and causes including the Licensor's rights to damages, rights to terminate the Licence or to convert the Licence from exclusive to a non-exclusive  basis arising as a result of Licensee's past performance under the Licence up to and including the Fourth Amendment Agreement Effective Date relating to any alleged failure of the Licensee to achieve certain developmental and commercial Milestones as originally contemplated by the parties.

5.  Governing Law

English  Law  governs  this  Fourth Amendment Agreement, and the  parties  submit  to  the exclusive jurisdiction of the English Courts for the resolution of any dispute which may arise out of or in connection with this Agreement save for injunctive relief which may be sought in any court of competent jurisdiction.

AS WITNESS this agreement has been executed by the duly authorized representatives of the parties, respectively, the date(s) written below.

	
			
	SIGNED for and on behalf of
	 
	SIGNED for and on behalf of

	ISIS INNOVATION LIMITED:
	 
	SEQUENOM, INC.:

	 
	 
	 

	NAME:     Mr. T Hockaday
	 
	NAME: Harry F. Hixson, Jr.

	Managing Director
	 
	 

	Isis Innovation Ltd
	 
	 

	 
	 
	 

	SIGNATURE: s/ Mr. T Hockaday
	 
	SIGNATURE: s/ Harry Hixson Jr.

	DATE:          November 29, 2012
	 
	DATE:      November 26, 2012

	 
	 
	 

    *** Confidential Treatment Requested
802573 v3/SDexhibit101_03282013.htm

Exhibit 10.1

  

  

  

Execution Version

 

 

THIRD AMENDMENT TO

 

THIRD AMENDED AND RESTATED

 

CREDIT AGREEMENT

 

 

Dated as of March 28, 2013

 

among

 

NORTHERN OIL AND GAS, INC.,

 

as Borrower,

 

ROYAL BANK OF CANADA,

 

as Administrative Agent,

 

and

 

The Lenders Party Hereto

 

 

 

  

  

  

THIRD AMENDMENT TO

 

THIRD AMENDED AND RESTATED CREDIT AGREEMENT

 

THIS THIRD AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of March 28, 2013, is by and among Northern Oil and Gas, Inc., a Minnesota corporation (the “Borrower”), Royal Bank of Canada (the “Administrative Agent”), and the Lenders party hereto.

 

Recitals

 

WHEREAS, the Borrower, the Administrative Agent and the other Lenders party thereto entered into that certain Third Amended and Restated Credit Agreement, dated as of February 28, 2012 (as previously amended by the First Amendment dated as of June 29, 2012 and by the Second Amendment dated as of September 28, 2012, and as the same may be further amended, modified, supplemented or restated from time to time, the “Credit Agreement”);

 

WHEREAS, the Borrower has requested that the Administrative Agent and the Lenders amend the Credit Agreement as set forth below; and

 

WHEREAS, the Administrative Agent and the Lenders are willing to (i) amend the Credit Agreement, (ii) redetermine the Borrowing Base as provided herein, and (iii) take such other actions as provided herein.

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and in the Credit Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

ARTICLE I

 

Definitions

 

Each capitalized term used in this Amendment and not defined herein shall have the meaning assigned to such term in the Credit Agreement.

 

ARTICLE II

 

Amendments to Credit Agreement

 

Section 2.01 Amendment to Section 8.01(k) of the Credit Agreement.  Section 8.01(k) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

 

  

1

  

 

 

(k)           Notice of Sales of Oil and Gas Properties.  In the event any Credit Party intends to sell, transfer, assign or otherwise dispose of in accordance with Section 9.12 (1) any Oil or Gas Properties, the proceeds of which equal or exceed $5,000,000, or (2) any Equity Interests in any other Credit Party, then such Credit Party must provide the Administrative Agent prior written notice of such disposition, the price thereof, the anticipated date of closing and any other details thereof requested by the Administrative Agent or any Lender.

 

Section 2.02 Amendment to Section 9.04 of the Credit Agreement.  Section 9.04 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

Section 9.04                      Dividends and Distributions.  The Borrower will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, return any capital to its stockholders or make any distribution of its Property to its Equity Interest holders, except (a) the Borrower may declare and pay dividends with respect to its Equity Interests payable solely in additional shares of its Equity Interests (other than Disqualified Capital Stock), (b) Subsidiaries may declare and pay dividends and make distributions to the Borrower with respect to their Equity Interests, (c) the Borrower may make Restricted Payments pursuant to and in accordance with stock option plans or other benefit plans for management or employees of the Credit Parties and (d) the Borrower may make Restricted Payments in an amount not to exceed, in the aggregate for all Restricted Payments under this subsection (d), (i) $60,000,000 plus (ii) 50% of Consolidated Net Income for the period from January 1, 2013 through the date of the Borrower’s most recently ended fiscal quarter, so long as (x) no Default or Event of Default has occurred and is continuing or would occur as a result of such Restricted Payments and (y) immediately following such Restricted Payments, the availability under the Borrowing Base, plus Borrower’s cash on hand, is equal to or greater than 10% of the Borrowing Base.  Solely for purposes of subsection (d) of this Section 9.01, “Consolidated Net Income” shall exclude (to the extent otherwise included therein) (x) noncash equity compensation expense and (y) noncash mark-to–market derivatives gains and losses.

 

Section 2.03 Amendment to Section 9.12(f) of the Credit Agreement.  Section 9.12(f) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

(f)           sales and other dispositions of Properties having a fair market value not to exceed $10,000,000 during any twelve (12) month period.

 

Section 2.04 Amendment to Annex I of the Credit Agreement.  Annex I of the Credit Agreement is hereby deleted in its entirety and replaced with Annex I hereto.

 

ARTICLE III

 

Redetermination of the Borrowing Base

 

Section 3.01 Redetermination of the Borrowing Base. Notwithstanding the requirements of Section 2.07 of the Credit Agreement, effective as of the Third Amendment Effective Date, the amount of the Borrowing Base shall be $400,000,000.00, subject to further adjustments from time to time pursuant to Section 2.07, Section 8.13(c) or Section 9.12(d) of the Credit Agreement. The redetermination of the Borrowing Base pursuant to this Section 3.01 of this Amendment shall constitute the Scheduled Redetermination for April 1, 2013.

 

ARTICLE IV

 

Conditions Precedent

 

This Amendment shall become effective as of the date first referenced above when and only when the following conditions are satisfied (the “Third Amendment Effective Date”):

 

(a) the Administrative Agent shall have received duly executed counterparts of this Amendment from the Borrower and each Lender, in such numbers as the Administrative Agent or its counsel may reasonably request; and

 

 

  

2

  

 

 

(b) the Administrative Agent and the Lenders shall have received such upfront fees as may be agreed to among the Borrower, the Administrative Agent and the Lenders with respect hereto and all other fees due and payable on or prior to the effectiveness hereof as provided in any Loan Document, including reimbursement or payment of all out-of-pocket expenses required to be reimbursed or paid by the Borrower under the Credit Agreement (including, without limitation, the reasonable fees and expenses of counsel to the Administrative Agent).

 

ARTICLE V

 

Representations and Warranties

 

The Borrower hereby represents and warrants to the Administrative Agent and each Lender that:

 

(a)           Each of the representations and warranties made by the Borrower under the Credit Agreement and each other Loan Document is true and correct on and as of the actual date of execution of this Amendment by the Borrower, as if made on and as of such date, except for any representations and warranties made as of a specified date, which are true and correct as of such specified date.

 

(b)           At the time of, and immediately after giving effect to, this Amendment, no Default has occurred and is continuing.

 

(c)           The execution, delivery and performance by the Borrower of this Amendment have been duly authorized by the Borrower.

 

(d)           This Amendment constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.

 

(e)           The execution, delivery and performance by the Borrower of this Amendment (i) do not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any other third Person (including the members or any class of directors of the Borrower or any other Person, whether interested or disinterested), nor is any such consent, approval, registration, filing or other action necessary for the validity or enforceability of any Loan Document or the consummation of the transactions contemplated thereby, except (a) such as have been obtained or made and are in full force and effect, and (b) the Borrower may need to file a current report on Form 8-K with the SEC disclosing this Amendment, (ii) will not violate any applicable law or regulation or the charter, by-laws or other organizational documents of the Borrower or any of its Subsidiaries or any order of any Governmental Authority, (iii) will not violate or result in a default under any indenture, agreement or other instrument binding upon the Borrower or any of its Subsidiaries or their Properties, or give rise to a right thereunder to require any payment to be made by the Borrower or such Subsidiary and (iv) will not result in the creation or imposition of any Lien on any Property of the Borrower or any of its Subsidiaries (other than the Liens created by the Loan Documents).

 

ARTICLE VI

 

Miscellaneous

 

Section 6.01 Credit Agreement in Full Force and Effect as Amended.  Except as specifically amended hereby, the Credit Agreement and other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed as so amended.  Except as expressly set forth herein, this Amendment shall not be deemed to be a waiver, amendment or modification of any provisions of the Credit Agreement or any other Loan Document or any right, power or remedy of the Administrative Agent or the Lenders, or constitute a waiver of any provision of the Credit Agreement or any other Loan Document, or any other document, instrument and/or agreement executed or delivered in connection therewith or of any Default or Event of Default under any of the foregoing, in each case whether arising before or after the date hereof or as a result of performance hereunder or thereunder.  This Amendment also shall not preclude the future exercise of any right, remedy, power, or privilege available to the Administrative Agent and/or the Lenders whether under the Credit Agreement, the other Loan Documents, at law or otherwise.  All references to the Credit Agreement shall be deemed to mean the Credit Agreement as modified hereby.  The parties hereto agree to be bound by the terms and conditions of the Credit Agreement and Loan Documents as amended by this Amendment, as though such terms and conditions were set forth herein.  Each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of similar import shall mean and be a reference to the Credit Agreement as amended by this Amendment, and each reference herein or in any other Loan Documents to the “Credit Agreement” shall mean and be a reference to the Credit Agreement as amended and modified by this Amendment.

 

 

  

3

  

 

 

Section 6.02 GOVERNING LAW.  THIS AMENDMENT, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER, SHALL BE CONSTRUED IN ACCORDANCE WITH AND BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

Section 6.03 Descriptive Headings, Etc.  The descriptive headings of the sections of this Amendment are inserted for convenience only and shall not be deemed to affect the meaning or construction of any of the provisions hereof.  The statements made and the terms defined in the recitals to this Amendment are hereby incorporated into this Amendment in their entirety.

 

Section 6.04 Entire Agreement.  This Amendment and the documents referred to herein represent the entire understanding of the parties hereto regarding the subject matter hereof and supersede all prior and contemporaneous oral and written agreements of the parties hereto with respect to the subject matter hereof.

 

Section 6.05 Loan Document.  This Amendment is a Loan Document executed under the Credit Agreement, and all provisions in the Credit Agreement pertaining to Loan Documents apply hereto.

 

Section 6.06 Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one agreement.  Delivery of an executed counterpart of the signature page of this Amendment by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart thereof.

 

Section 6.07 Successors.  The execution and delivery of this Amendment by any Lender shall be binding upon each of its successors and assigns.

 

 

(Remainder of page intentionally left blank.)

 

 

 

  

4

  

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the date first written above.

 

NORTHERN OIL AND GAS, INC., as the Borrower

 

By:           /s/ Thomas W. Stoelk                                                                

Name:            Thomas W. Stoelk

Title:              CFO

Signature Page

Third Amendment to Credit Agreement

 

  

  

  

 

 

ROYAL BANK OF CANADA, as Administrative Agent

By:           /s/ Rodica Dutka         

Name:           Rodica Dutka

Title:             Manager, Agency

ROYAL BANK OF CANADA, as a Lender

By:           /s/ Kristan Spivey         

Name:            Kristan Spivey

Title:              Authorized Signatory

SUNTRUST BANK, as a Lender

By:           /s/ Yann Pirio           

Name:            Yann Pirio

Title:               Director

BMO HARRIS FINANCING, INC., as a Lender

By:           /s/ Joseph A. Bliss         

Name:            Joseph A. Bliss

Title:              Managing Director

KEYBANK NATIONAL ASSOCIATION, as a Lender

By:           /s/ Chulley Bogle         

Name:            Chulley Bogle

Title:              Vice President

U.S. BANK NATIONAL ASSOCIATION, as a Lender

By:           /s/ Daniel K. Hansen        

Name:            Daniel K. Hansen

Title:              Vice President

SOVEREIGN BANK, N.A., as a Lender

By:           /s/ Aidan Lanigan         

Name:            Aidan Lanigan

Title:              SVP

CAPITAL ONE, NATIONAL ASSOCIATION, as a Lender

By:           /s/ Robert S. James         

Name:            Robert S. James

Title:              Vice President

BOKF, NA dba BANK OF OKLAHOMA, as a Lender

By:           /s/ Guy C. Evangelista       

Name:            Guy C. Evangelista

Title:              Senior Vice President

BRANCH BANKING & TRUST COMPANY, as a Lender

By:           /s/ Jodie Gildersleeve            

Name:            Jodie Gildersleeve

Title:              Banking Officer

CADENCE BANK, N.A., as a Lender

By:           /s/ Eric Broussard                

Name:            Eric Broussard

Title:              Senior Vice President

Signature Page

Third Amendment to Credit Agreement

  

  

  

MACQUARIE BANK LIMITED, as a Lender

By:           /s/ Carmel Ferguson      

Name:            Carmel Ferguson

Title:              Executive Director

By:           /s/ Simon Berkett          

Name:            Simon Berkett

Title:              Associate Director

THE BANK OF NOVA SCOTIA, as a Lender

By:           /s/ Terry Donovan      

Name:            Terry Donovan

Title:               Managing Director

ING CAPITAL LLC, as a Lender

By:           /s/ Charles Hall             

Name:            Charles Hall

Title:              Managing Director

Signature Page

Third Amendment to Credit Agreement

 

  

  

  

ANNEX I

	
Name of Lender

	 	
Applicable

Percentage

	 	 	
Maximum Credit Amount

	 	 	
Amount of Commitment on the Third Amendment Effective Date

	 
	
Royal Bank of Canada

	 	 	12.0	%	 	$	90,000,000.00	 	 	$	48,000,000.00	 
	
SunTrust Bank

	 	 	12.0	%	 	$	90,000,000.00	 	 	$	48,000,000.00	 
	
BMO Harris Financing, Inc.

	 	 	8.6	%	 	$	64,285,714.29	 	 	$	34,285,714.29	 
	
KeyBank, N.A.

	 	 	8.6	%	 	$	64,285,714.29	 	 	$	34,285,714.29	 
	
U.S. Bank National Association

	 	 	8.6	%	 	$	64,285,714.29	 	 	$	34,285,714.29	 
	
Capital One, National Association

	 	 	7.4	%	 	$	55,714,285.71	 	 	$	29,714,285.71	 
	
Sovereign Bank, N.A.

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
BOKF, NA dba Bank of Oklahoma

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
Branch Banking & Trust Co.

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
Cadence Bank, N.A.

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
ING Capital LLC

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
The Bank of Nova Scotia

	 	 	6.9	%	 	$	51,428,571.43	 	 	$	27,428,571.43	 
	
Macquarie Bank Limited

	 	 	1.70	%	 	$	12,857,142.86	 	 	$	6,857,142.86	 
	  	 	 	 	 	 	 	 	 	 	 	 	 
	
TOTAL

	 	 	100.00	%	 	$	750,000,000.00	 	 	$	400,000,000.00	 

Third Amendment to Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]